Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
6.58 (1y: +21%)
Market Cap 231.6 M P/E(ttm)
Enterprise Value 180.98 M P/B 3.30
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt No Debt
ZLTQ's Cash to Debt is ranked higher than
83% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. ZLTQ: No Debt )
ZLTQ' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: No Debt
Equity to Asset 0.804
ZLTQ's Equity to Asset is ranked higher than
84% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ZLTQ: 0.804 )
ZLTQ' s 10-Year Equity to Asset Range
Min: -9.69   Max: 0.89
Current: 0.8
-9.69
0.89
Interest Coverage No Debt
ZLTQ's Interest Coverage is ranked higher than
78% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. ZLTQ: No Debt )
ZLTQ' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
Z-Score: 6.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -39.40
ZLTQ's Operating margin (%) is ranked lower than
65% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ZLTQ: -39.40 )
ZLTQ' s 10-Year Operating margin (%) Range
Min: -1082.2   Max: -12.8
Current: -39.4
-1082.2
-12.8
Net-margin (%) -39.6
ZLTQ's Net-margin (%) is ranked lower than
64% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. ZLTQ: -39.6 )
ZLTQ' s 10-Year Net-margin (%) Range
Min: -1111.8   Max: -14.1
Current: -39.6
-1111.8
-14.1
ROE (%) -41.5
ZLTQ's ROE (%) is ranked lower than
66% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. ZLTQ: -41.5 )
ZLTQ' s 10-Year ROE (%) Range
Min: -41.5   Max: -10.2
Current: -41.5
-41.5
-10.2
ROA (%) -33.4
ZLTQ's ROA (%) is ranked lower than
66% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ZLTQ: -33.4 )
ZLTQ' s 10-Year ROA (%) Range
Min: -254.7   Max: -9.1
Current: -33.4
-254.7
-9.1
ROC (Joel Greenblatt) (%) -463.10
ZLTQ's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. ZLTQ: -463.10 )
ZLTQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1729.6   Max: -301.2
Current: -463.1
-1729.6
-301.2
» ZLTQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ZLTQ Guru Trades in Q2 2012

Chuck Royce 900,000 sh (New)
» More
Q3 2012

ZLTQ Guru Trades in Q3 2012

Chuck Royce 900,000 sh (unchged)
» More
Q4 2012

ZLTQ Guru Trades in Q4 2012

Chuck Royce 900,000 sh (unchged)
» More
Q1 2013

ZLTQ Guru Trades in Q1 2013

Chuck Royce 765,000 sh (-15%)
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 3.30
ZLTQ's P/B is ranked higher than
54% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ZLTQ: 3.30 )
ZLTQ' s 10-Year P/B Range
Min: 1.78   Max: 4.34
Current: 3.3
1.78
4.34
P/S 3.00
ZLTQ's P/S is ranked higher than
57% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ZLTQ: 3.00 )
ZLTQ' s 10-Year P/S Range
Min: 0.29   Max: 2.8
Current: 3
0.29
2.8
EV-to-EBIT 7.7
ZLTQ's EV-to-EBIT is ranked higher than
54% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. ZLTQ: 7.7 )
ZLTQ' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 7.7

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 8.1
ZLTQ's Price/Net Cash is ranked higher than
79% of the 90 Companies
in the Global Medical Devices industry.

( Industry Median: 10.50 vs. ZLTQ: 8.1 )
ZLTQ' s 10-Year Price/Net Cash Range
Min: 1.2   Max: 5.8
Current: 8.1
1.2
5.8
Price/Net Current Asset Value 19.8
ZLTQ's Price/Net Current Asset Value is ranked higher than
58% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. ZLTQ: 19.8 )
ZLTQ' s 10-Year Price/Net Current Asset Value Range
Min: 5.5   Max: 14
Current: 19.8
5.5
14
Price/Tangible Book 3.5
ZLTQ's Price/Tangible Book is ranked higher than
62% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. ZLTQ: 3.5 )
ZLTQ' s 10-Year Price/Tangible Book Range
Min: 1   Max: 2.5
Current: 3.5
1
2.5
Price/Median PS Value 1.9
ZLTQ's Price/Median PS Value is ranked lower than
63% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ZLTQ: 1.9 )
ZLTQ' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.4
Current: 1.9
0.6
1.4

Business Description

ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. It is a medical technology company focused on the development and commercialization of products utilizing its proprietary controlled-cooling technology platform. Its first commercial product, the CoolSculpting System, selectively reduces stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. It developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise. It selectively markets CoolSculpting to those dermatologists, plastic surgeons, and aesthetic specialists who it identifies as having significant experience in performing aesthetic procedures as well as a willingness to position CoolSculpting as a premium, differentiated treatment. CoolSculpting provides the following benefits to its physician customers and their patients: clinically proven, consistent and durable results; excellent safety profile; enhanced patient satisfaction; repeatability enabled by natural biological process and differentiated, high-value product for physician practices. Its strategy is to establish CoolSculpting as a premium, highly-differentiated treatment through selective distribution; increase utilization of CoolSculpting through its targeted physician marketing and support programs; increase consumer awareness and demand for CoolSculpting; increase its international presence; expand its FDA-cleared indications for CoolSculpting and leverage its technology platform. The Company's tradenamens are ZELTIQ, CoolSculpting, CoolCard, CoolCurve, CoolCore, CoolMax.
Company Website
SEC Reports
Industry: Medical Devices
Compare:
» More Articles for ZLTQ

Headlines

Articles On GuruFocus.com
4 Stocks To Buy, 1 To Avoid In 2012 Feb 18 2012 
Weekly CFO Sales Highlight: INFA, DHR, AN, SMTC, ZLTQ Oct 31 2011 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK